HK1251239A1 - 工程改造免疫球蛋白的方法 - Google Patents

工程改造免疫球蛋白的方法

Info

Publication number
HK1251239A1
HK1251239A1 HK18110606.5A HK18110606A HK1251239A1 HK 1251239 A1 HK1251239 A1 HK 1251239A1 HK 18110606 A HK18110606 A HK 18110606A HK 1251239 A1 HK1251239 A1 HK 1251239A1
Authority
HK
Hong Kong
Prior art keywords
engineering immunoglobulins
immunoglobulins
engineering
Prior art date
Application number
HK18110606.5A
Other languages
English (en)
Inventor
Gottfried Himmler
Gerda Redl
Florian RÜCKER
Gordana Wozniak-Knopp
Original Assignee
F Star Biotechnologische Forschungs Und Entw M B H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Star Biotechnologische Forschungs Und Entw M B H filed Critical F Star Biotechnologische Forschungs Und Entw M B H
Publication of HK1251239A1 publication Critical patent/HK1251239A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/16—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from plants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Botany (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK18110606.5A 2006-07-05 2018-08-17 工程改造免疫球蛋白的方法 HK1251239A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0114506A AT503902B1 (de) 2006-07-05 2006-07-05 Verfahren zur manipulation von immunglobulinen

Publications (1)

Publication Number Publication Date
HK1251239A1 true HK1251239A1 (zh) 2019-01-25

Family

ID=38871148

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110606.5A HK1251239A1 (zh) 2006-07-05 2018-08-17 工程改造免疫球蛋白的方法

Country Status (15)

Country Link
US (4) US9133274B2 (zh)
EP (2) EP3293200B1 (zh)
JP (1) JP5508002B2 (zh)
CN (2) CN109777804A (zh)
AT (1) AT503902B1 (zh)
CY (1) CY1119641T1 (zh)
DK (1) DK2044117T3 (zh)
ES (2) ES2650437T3 (zh)
HK (1) HK1251239A1 (zh)
HU (1) HUE037426T2 (zh)
LT (1) LT2044117T (zh)
PL (1) PL2044117T3 (zh)
PT (1) PT2044117T (zh)
SI (1) SI2044117T1 (zh)
WO (1) WO2008003116A2 (zh)

Families Citing this family (139)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1772465T1 (sl) 2005-01-05 2009-06-30 F Star Biotech Forsch & Entw Sintetične imunoglobulinske domene z modificiranimi vezavnimi lastnostmi v regijah molekule, ki se razlikujejo od komplementarnost dolučujočih regij
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
PL3241842T3 (pl) * 2007-06-26 2024-06-10 F-Star Therapeutics Limited Prezentacja środków wiążących
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
US8510275B2 (en) * 2009-09-21 2013-08-13 Dell Products L.P. File aware block level deduplication
EP2598530A2 (en) 2010-07-29 2013-06-05 Xencor, Inc. Antibodies with modified isoelectric points
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
EP3388451A1 (en) 2011-09-29 2018-10-17 Apo-T B.V. Multi specific binding molecules targeting aberrant cells
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013105856A1 (en) 2012-01-13 2013-07-18 Apo-T B.V. Aberrant cell-restricted immunoglobulins provided with a toxic moiety
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
BR112015000167B1 (pt) 2012-07-06 2021-11-23 Genmab B.V. Proteína dimérica, proteína, composição, kit de partes e seus usos, bem como método para aumentar a oligomerização em solução de uma proteína dimérica compreendendo um primeiro e segundo polipeptídeo, cada um compreendendo pelo menos as regiões ch2 e ch3 de uma cadeia pesada de igg1 humana e proteína dimérica variante
EP2912068B1 (en) * 2012-10-26 2019-06-19 Deutsches Rheuma-Forschungszentrum Berlin Bi-specific antibodies for cell-lineage-specific tnf-alpha neutralisation
EP2943506B1 (en) 2013-01-10 2024-03-13 Genmab B.V. Human igg1 fc region variants and uses thereof
CN105051069B (zh) 2013-01-14 2019-12-10 Xencor股份有限公司 新型异二聚体蛋白
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
CA2897987A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
AU2014232416B2 (en) 2013-03-15 2017-09-28 Xencor, Inc. Modulation of T Cells with Bispecific Antibodies and FC Fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
EP3003370B1 (en) * 2013-05-28 2020-01-22 Dcb-Usa Llc Antibody locker for the inactivation of protein drug
ME03675B (me) 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
WO2015021080A2 (en) 2013-08-05 2015-02-12 Twist Bioscience Corporation De novo synthesized gene libraries
US10545918B2 (en) 2013-11-22 2020-01-28 Orbis Technologies, Inc. Systems and computer implemented methods for semantic data compression
EA201691925A1 (ru) 2014-03-28 2017-06-30 Ксенкор, Инк. Биспецифические антитела, которые связываются с cd38 и cd3
EP3148580B1 (en) 2014-05-29 2021-01-20 MacroGenics, Inc. Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
AU2015286569B2 (en) 2014-07-11 2021-04-15 Genmab A/S Antibodies binding AXL
AP2017009823A0 (en) 2014-09-26 2017-03-31 Macrogenics Inc Bi-specific monovalent diabodies that are capable of binding cd19 and cd3, and uses thereof
BR112017011092A2 (pt) 2014-11-26 2017-12-26 Xencor Inc anticorpos heterodiméricos que ligam cd3 e antígenos de tumor
PE20171103A1 (es) 2014-11-26 2017-08-07 Xencor Inc Anticuerpos heterodimericos que se unen a cd3 y cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
CN104403001B (zh) * 2014-12-12 2018-01-16 中国人民解放军***军事医学研究所 一种全人源抗TLR4的抗体Fab及其全分子抗体IgG和应用
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
EP3250601A4 (en) 2015-01-26 2018-07-11 MacroGenics, Inc. Multivalent molecules comprising dr5-binding domains
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US9981239B2 (en) 2015-04-21 2018-05-29 Twist Bioscience Corporation Devices and methods for oligonucleic acid library synthesis
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
DK3319993T3 (da) 2015-07-10 2020-04-20 Genmab As AXL-SPECIFIKKE antistof-lægemiddelkonjugater til kræftbehandling
BR112018000696A2 (pt) 2015-07-15 2018-09-18 Genmab As ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
SI3456346T1 (sl) 2015-07-30 2021-11-30 Macrogenics, Inc. Molekule za vezavo PD-1 in LAG-3 in postopki za uporabo le-teh
KR20180050411A (ko) 2015-09-18 2018-05-14 트위스트 바이오사이언스 코포레이션 올리고핵산 변이체 라이브러리 및 그의 합성
CN113604546A (zh) 2015-09-22 2021-11-05 特韦斯特生物科学公司 用于核酸合成的柔性基底
WO2017062619A2 (en) 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
US10227410B2 (en) 2015-12-07 2019-03-12 Xencor, Inc. Heterodimeric antibodies that bind CD3 and PSMA
GEP20217328B (en) 2015-12-14 2021-12-10 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
MA44074A (fr) * 2015-12-18 2018-10-24 Eisai R&D Man Co Ltd Immunoglobulines conjuguées à la lysine c-terminale
US20170233472A1 (en) 2016-02-17 2017-08-17 Macrogenics, Inc. ROR1-Binding Molecules, and Methods of Use Thereof
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE
MX2018015592A (es) 2016-06-14 2019-04-24 Xencor Inc Anticuerpos inhibidores de puntos de control biespecificos.
JP7021127B2 (ja) 2016-06-28 2022-02-16 ゼンコア インコーポレイテッド ソマトスタチン受容体２に結合するヘテロ二量体抗体
KR102632202B1 (ko) 2016-07-14 2024-02-02 젠맵 에이/에스 Cd40 및 cd137에 대한 다중특이적 항체
GB2568444A (en) 2016-08-22 2019-05-15 Twist Bioscience Corp De novo synthesized nucleic acid libraries
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
WO2018057526A2 (en) 2016-09-21 2018-03-29 Twist Bioscience Corporation Nucleic acid based data storage
MX2019004327A (es) 2016-10-14 2019-10-14 Xencor Inc Proteinas de fusion heterodimericas biespecificas que contienen proteinas de fusion fc il-15/il-15ra y fragmentos de anticuerpo pd-1.
MA46700A (fr) 2016-11-01 2021-05-19 Genmab Bv Variants polypeptidiques et ses utilisations
AR110424A1 (es) 2016-12-23 2019-03-27 Macrogenics Inc Moléculas de unión a adam9 y métodos de uso de las mismas
AU2018218345A1 (en) 2017-02-10 2019-08-29 Genmab B.V. Polypeptide variants and uses thereof
WO2018152326A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Engineered transferrin receptor binding polypeptides
CA3054303A1 (en) 2017-02-22 2018-08-30 Twist Bioscience Corporation Nucleic acid based data storage
IL268836B2 (en) 2017-02-24 2024-04-01 Macrogenics Inc Bispecific molecules that bind CD137 and cancer antigens and their uses
JP7293121B2 (ja) 2017-03-09 2023-06-19 ジェンマブ エー／エス Ｐｄ－ｌ１に対する抗体
WO2018170169A1 (en) 2017-03-15 2018-09-20 Twist Bioscience Corporation Variant libraries of the immunological synapse and synthesis thereof
KR20200074915A (ko) 2017-03-31 2020-06-25 젠맵 홀딩 비.브이. 이중특이적 항-cd37 항체, 모노클로날 항-cd37 항체 및 그의 사용 방법
MA49259A (fr) 2017-06-07 2020-04-15 Genmab Bv Anticorps thérapeutiques à base d'hexamères d'igg mutées
WO2018231864A1 (en) 2017-06-12 2018-12-20 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
AU2018284227B2 (en) 2017-06-12 2024-05-02 Twist Bioscience Corporation Methods for seamless nucleic acid assembly
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
SG11202000801QA (en) 2017-07-31 2020-02-27 Univ Tokyo Highly versatile method of presenting cyclic peptide on protein structure
SG11202000198QA (en) 2017-08-04 2020-02-27 Genmab As Binding agents binding to pd-l1 and cd137 and use thereof
CA3075505A1 (en) 2017-09-11 2019-03-14 Twist Bioscience Corporation Gpcr binding proteins and synthesis thereof
SG11202003574TA (en) 2017-10-20 2020-05-28 Twist Bioscience Corp Heated nanowells for polynucleotide synthesis
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018366199A1 (en) 2017-11-08 2020-05-28 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
KR20200098590A (ko) 2017-12-12 2020-08-20 마크로제닉스, 인크. 이중특이적 cd16-결합 분자 및 질환 치료에서의 그것의 용도
JP2021506291A (ja) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド 改変されたｉｌ−２ ｆｃ融合タンパク質
EP3743440A1 (en) 2018-01-24 2020-12-02 Genmab B.V. Polypeptide variants and uses thereof
US11685781B2 (en) 2018-02-15 2023-06-27 Macrogenics, Inc. Variant CD3-binding domains and their use in combination therapies for the treatment of disease
CR20200463A (es) 2018-03-12 2021-03-31 Genmab As Anticuerpos
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
CA3097741A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
SG11202010601VA (en) 2018-05-03 2020-11-27 Genmab Bv Antibody variant combinations and uses thereof
GB2590196A (en) 2018-05-18 2021-06-23 Twist Bioscience Corp Polynucleotides, reagents, and methods for nucleic acid hybridization
JP7513530B2 (ja) 2018-06-22 2024-07-09 ジェンマブ ホールディング ビー．ブイ． 抗ｃｄ３７抗体および抗ｃｄ２０抗体、組成物、ならびにそれらの使用方法
SG11202012993SA (en) 2018-07-13 2021-02-25 Genmab As Variants of cd38 antibody and uses thereof
JP2021526845A (ja) 2018-07-13 2021-10-11 ゲンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
WO2020027224A1 (ja) * 2018-07-31 2020-02-06 国立大学法人東京大学 新たな結合特異性を抗体に付与する超汎用法
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
MA53812A (fr) 2018-10-04 2021-08-11 Genmab Holding B V Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
IL308722A (en) 2018-10-17 2024-01-01 Biolinerx Ltd Treatment of metastatic adenocarcinoma of the pancreas
KR20210124959A (ko) 2018-11-06 2021-10-15 젠맵 에이/에스 항체 제제
US20220010301A1 (en) * 2018-11-14 2022-01-13 Cowper Sciences Inc. Methods of selecting functional interface mimics, and compositions thereof
US11492728B2 (en) 2019-02-26 2022-11-08 Twist Bioscience Corporation Variant nucleic acid libraries for antibody optimization
WO2020176678A1 (en) * 2019-02-26 2020-09-03 Twist Bioscience Corporation Variant nucleic acid libraries for glp1 receptor
CN114173875A (zh) 2019-03-01 2022-03-11 Xencor股份有限公司 结合enpp3和cd3的异二聚抗体
WO2020225456A1 (en) 2019-05-09 2020-11-12 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
WO2020257612A1 (en) 2019-06-21 2020-12-24 Twist Bioscience Corporation Barcode-based nucleic acid sequence assembly
EP4055046A1 (en) 2019-11-06 2022-09-14 Genmab B.V. Antibody variant combinations and uses thereof
AU2021208532A1 (en) 2020-01-16 2022-07-07 Genmab A/S Formulations of CD38 antibodies and uses thereof
IL272194A (en) 2020-01-22 2021-07-29 Yeda Res & Dev Multi-target antibodies for use in the treatment of diseases
IL272389A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Kits containing antibodies to PD-L1 and their uses in therapy
IL272390A (en) 2020-01-30 2021-08-31 Yeda Res & Dev Cancer treatment methods
WO2021155916A1 (en) 2020-02-04 2021-08-12 BioNTech SE Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
EP4121456A1 (en) 2020-03-18 2023-01-25 Genmab A/S Antibodies binding to b7h4
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
EP4175650A1 (en) 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
WO2022018294A1 (en) 2020-07-23 2022-01-27 Genmab B.V. A combination of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma
EP4192859A1 (en) 2020-08-06 2023-06-14 BioNTech SE Binding agents for coronavirus s protein
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
KR20230066583A (ko) 2020-09-10 2023-05-16 젠맵 에이/에스 미만성 대 b-세포 림프종을 치료하기 위한 조합 요법에서의 cd3 및 cd20에 대한 이중특이적 항체
US20230312757A1 (en) 2020-09-10 2023-10-05 Genmab A/S Bispecific antibodies against cd3 and cd20 for treating chronic lymphocytic leukemia
AU2021351187A1 (en) 2020-10-02 2023-04-20 Genmab A/S Antibodies capable of binding to ROR2 and bispecific antibodies binding to ROR2 and CD3
CA3202233A1 (en) 2020-11-18 2022-05-27 Kiromic BioPharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
KR20230154311A (ko) 2021-03-10 2023-11-07 젠코어 인코포레이티드 Cd3 및 gpc3에 결합하는 이종이량체 항체
BR112023017887A2 (pt) 2021-03-12 2023-10-10 Genmab As Proteína compreendendo um primeiro polipeptídeo e um segundo polipeptídeo, anticorpo biespecífico, ácido nucleico de codificação do dito primeiro ou segundo polipeptídeo, célula hospedeira, composição farmacêutica, proteína, anticorpo biespecífico ou composição farmacêutica para uso, e, métodos de tratamento e de preparo de um anticorpo biespecífico
AU2022261725A1 (en) * 2021-04-19 2023-12-07 Janssen Biotech, Inc. Molecules with engineered antibody constant region variants
EP4334359A1 (en) 2021-05-07 2024-03-13 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies binding to b7h4 and cd3
CA3223375A1 (en) 2021-06-21 2022-12-29 Ugur Sahin Combination dosage regime of cd137 and pd-l1 binding agents
IL311141A (en) 2021-09-06 2024-04-01 Genmab As Antibodies capable of binding to CD27, their variants and uses thereof
IL286430A (en) 2021-09-14 2023-04-01 Yeda Res & Dev Multispecific antibodies for use in the treatment of diseases
KR20240082397A (ko) 2021-10-08 2024-06-10 젠맵 에이/에스 Cd30 및 cd3에 결합하는 항체
WO2023174521A1 (en) 2022-03-15 2023-09-21 Genmab A/S Binding agents binding to epcam and cd137
WO2023218046A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023218051A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
US20240132624A1 (en) 2022-07-27 2024-04-25 Ablynx N.V. Polypeptides binding to a specific epitope of the neonatal fc receptor
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492107B1 (en) * 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
EP0590689B2 (fr) * 1985-03-30 2006-08-16 KAUFFMAN, Stuart A. Procédé d'obtention d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombinaison d'ADN
EP0438310A1 (en) * 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
JP3283041B2 (ja) * 1990-07-13 2002-05-20 学校法人藤田学園 人工抗体
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
GB9501079D0 (en) * 1995-01-19 1995-03-08 Bioinvent Int Ab Activation of T-cells
US6361974B1 (en) 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
CA2249195A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6180343B1 (en) 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
IL138002A0 (en) 1999-01-19 2001-10-31 Maxygen Inc Methods for making character strings, polynucleotides and polypeptides having desired characteristics
US20010044111A1 (en) 2000-03-20 2001-11-22 Brian Carr Method for generating recombinant DNA molecules in complex mixtures
AU2001261628A1 (en) 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
EP1281757A1 (en) 2001-07-31 2003-02-05 Direvo Biotech AG Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids
US7317091B2 (en) * 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1394251A1 (en) 2002-08-23 2004-03-03 Direvo Biotech AG Method for the selective randomization of polynucleotides
JP2006520584A (ja) 2002-11-08 2006-09-14 アブリンクス エン．ヴェー． 安定化単一ドメイン抗体
EP2053062A1 (en) * 2004-03-24 2009-04-29 Xencor, Inc. Immunoglobin variants outside the Fc region
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
AU2005289685B2 (en) * 2004-09-24 2009-07-16 Amgen Inc. Modified Fc molecules
SI1772465T1 (sl) * 2005-01-05 2009-06-30 F Star Biotech Forsch & Entw Sintetične imunoglobulinske domene z modificiranimi vezavnimi lastnostmi v regijah molekule, ki se razlikujejo od komplementarnost dolučujočih regij
AT503889B1 (de) * 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
EP2113255A1 (en) * 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin

Also Published As

Publication number Publication date
SI2044117T1 (en) 2018-01-31
PT2044117T (pt) 2017-12-07
WO2008003116A2 (en) 2008-01-10
EP3293200A1 (en) 2018-03-14
US20170369868A1 (en) 2017-12-28
PL2044117T3 (pl) 2018-02-28
US20210388339A1 (en) 2021-12-16
CN101528775A (zh) 2009-09-09
CN109777804A (zh) 2019-05-21
ES2650437T3 (es) 2018-01-18
US20100029497A1 (en) 2010-02-04
WO2008003116A3 (en) 2008-04-24
HUE037426T2 (hu) 2018-08-28
EP2044117A2 (en) 2009-04-08
AT503902A1 (de) 2008-01-15
EP2044117B1 (en) 2017-09-06
JP2009541361A (ja) 2009-11-26
CY1119641T1 (el) 2018-04-04
US20150376603A1 (en) 2015-12-31
LT2044117T (lt) 2017-12-11
JP5508002B2 (ja) 2014-05-28
US9133274B2 (en) 2015-09-15
AT503902B1 (de) 2008-06-15
EP3293200C0 (en) 2024-01-03
DK2044117T3 (en) 2017-12-04
ES2968247T3 (es) 2024-05-08
EP3293200B1 (en) 2024-01-03

Similar Documents

Publication Publication Date Title
HK1251239A1 (zh) 工程改造免疫球蛋白的方法
GB0601961D0 (en) Method
GB0603081D0 (en) Method
GB0607317D0 (en) Method
GB0606147D0 (en) Method
GB0618001D0 (en) Method
GB0605323D0 (en) Method
GB0603008D0 (en) Method
GB0604018D0 (en) Method
GB0601699D0 (en) Method
GB0602986D0 (en) Method
GB0618046D0 (en) Method
GB0606954D0 (en) Method
EP2053054A4 (en) PROCESS FOR INTRODUCING A NUCLEIC ACID PROTECTION GROUP
TWI340345B (en) Method for selecting critical variables
GB0618656D0 (en) Method
GB0612342D0 (en) Method
GB0612014D0 (en) Method
GB0611391D0 (en) Method
GB0610949D0 (en) Method
GB0617274D0 (en) Method
GB0610338D0 (en) Method
GB0609901D0 (en) Method
GB0602830D0 (en) Method
PL381143A1 (pl) Sposób otrzymywania 2-metyloglicydolu